
Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
Supplements and Featured Publications
over 23 years ago
Case reports illustrate consequences of ATP III in practiceover 23 years ago
Inflammatory markers are useful risk assessment toolsover 23 years ago
IVUS is redefining atherosclerotic disease


